CDK4 and melanoma: After excluding 246 patients with missing information on MITF mutational status, 133 patients either positive for CDKN2A/CDK4 pathogenic variants or with missing information on CDKN2A/CDK4 germline status, and 23 patients affected by ocular or mucosal melanomas, our study cohort comprised 984 cutaneous melanoma patients, 22 MITF+ and 962 MITF− (Fig. 1).